Literature DB >> 9630160

Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse.

A Gayo1, L Mozo, A Suárez, A Tuñon, C Lahoz, C Gutiérrez.   

Abstract

High doses of glucocorticoids (GCs) are widely employed to treat acute attacks in relapsing-remitting multiple sclerosis (MS) patients. Their beneficial effects are partially due to their capacity to regulate the cytokine network. In the present work, we have examined the effect of GCs on the production of the immunosuppressor cytokine IL-10. Blood samples from MS patients suffering an acute relapse were obtained immediately before initiating therapy and after receiving a daily dose of 1 g intravenous methylprednisolone (MP) for four days. Levels of IL-10 mRNA in PBMC were semiquantified by RT-PCR, whereas protein concentration in serum and in cell culture supernatant was measured by ELISA. Our results show that 7 out of the 9 patients studied displayed increased IL-10 mRNA expression as well as higher serum IL-10 concentration following steroid treatment. In contrast, mRNA expression of two inflammatory cytokines, TNFalpha and IFNgamma, decreased following steroid therapy. In vitro experiments employing normal PBMC showed that methylprednisolone (MP) upregulated IL-10 expression as determined by measuring mRNA levels, flow cytometry of intracytoplasmic protein concentration, and the amount of secreted protein. Peak responses of secreted IL-10 by PBMC cultured cells treated with MP were obtained at 48 h. The effect was steroid-specific as IL-10 expression reversed to baseline levels in the presence of the glucocorticoid receptor antagonist RU486. Contrary to the effect of MP on the spontaneous expression of IL-10, this drug downregulated LPS-induced IL-10 synthesis. In fact, the concentration of IL-10 in LPS-induced IL-10 secretion from normal PBMC decreased upon addition of MP to cell cultures. Thus, it seems that MP exerts an opposite effect on the spontaneous and LPS-induced IL-10 production. Our studies indicate that GCs may control inflammatory responses by upregulating production of the immunosuppressor cytokine IL-10.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9630160     DOI: 10.1016/s0165-5728(97)00262-2

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  12 in total

Review 1.  Myeloid cells - targets of medication in multiple sclerosis.

Authors:  Manoj K Mishra; V Wee Yong
Journal:  Nat Rev Neurol       Date:  2016-08-12       Impact factor: 42.937

2.  Effects of prednisolone treatment on cytokine expression in patients with leprosy type 1 reactions.

Authors:  Anna K Andersson; MeherVani Chaduvula; Sara E Atkinson; Saroj Khanolkar-Young; Suman Jain; Lavanya Suneetha; Sujai Suneetha; Diana N J Lockwood
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

3.  Suppression of immune system genes by methylprednisolone in exacerbations of multiple sclerosis. Preliminary results.

Authors:  Nina Airla; Mari Luomala; Irina Elovaara; Eeva Kettunen; Sakari Knuutila; Terho Lehtimäki
Journal:  J Neurol       Date:  2004-10       Impact factor: 4.849

4.  Increased interferon-gamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE).

Authors:  A Csiszár; G Nagy; P Gergely; T Pozsonyi; E Pócsik
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

5.  Mechanisms of the anti-inflammatory effects of the natural secosteroids physalins in a model of intestinal ischaemia and reperfusion injury.

Authors:  Angélica T Vieira; Vanessa Pinho; Lucilia B Lepsch; Cristóforo Scavone; Ivone M Ribeiro; Therezinha Tomassini; Ricardo Ribeiro-dos-Santos; Milena B P Soares; Mauro M Teixeira; Danielle G Souza
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

6.  Analysis of Micro-RNA-144 Expression Profile in Patients with Multiple Sclerosis in Comparison with Healthy Individuals.

Authors:  Fatemeh Roshani; Hossien Delavar Kasmaee; Kowsar Falahati; Ghazaleh Arabzade; Atefeh Sohan Forooshan Moghadam; Mohammad Hossein Sanati
Journal:  Rep Biochem Mol Biol       Date:  2021-10

7.  Treatment of multiple sclerosis with methylprednisolone and mitoxantrone modulates the expression of CXC chemokine receptors in PBMC.

Authors:  Bartosz Bielecki; Andzelika Mazurek; Paweł Wolinski; Andrzej Glabinski
Journal:  J Clin Immunol       Date:  2007-10-25       Impact factor: 8.317

8.  Medroxyprogesterone acetate differentially regulates interleukin (IL)-12 and IL-10 in a human ectocervical epithelial cell line in a glucocorticoid receptor (GR)-dependent manner.

Authors:  Renate Louw-du Toit; Janet P Hapgood; Donita Africander
Journal:  J Biol Chem       Date:  2014-09-08       Impact factor: 5.157

9.  Glucocorticoids increase CD4CD25 cell percentage and Foxp3 expression in patients with multiple sclerosis.

Authors:  M Braitch; S Harikrishnan; R A Robins; C Nichols; A J Fahey; L Showe; C S Constantinescu
Journal:  Acta Neurol Scand       Date:  2009-04       Impact factor: 3.209

10.  IL-22, GM-CSF and IL-17 in peripheral CD4+ T cell subpopulations during multiple sclerosis relapses and remission. Impact of corticosteroid therapy.

Authors:  Nathalie Muls; Zakia Nasr; Hong Anh Dang; Christian Sindic; Vincent van Pesch
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.